TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #14895 · Jul 2

#python#copilot#csharp#dotnet#github#github_copilot#github_copilot_chat#github_copilot_for_azure#github_copilot_free#github_copilot_training#javascript#lab#labs#microsoft#python#sql#tutorial#tutorial_code#tutorial_exercises#visual_studio_code#vscode GitHub Copilot’s new Agent Mode is a powerful AI coding partner that goes beyond just suggesting code—it can independently write, debug, and improve your code, handle complex workflows, and even fix its own mistakes automatically. It works with multiple programming languages and integrates with popular development tools, helping you save time on repetitive tasks like testing, deployment, and refactoring. By using natural language prompts, you can guide it to complete multi-step projects, making coding faster and easier whether you’re a beginner or an expert. This course teaches you how to fully use these features, boosting your productivity and coding skills. https://github.com/microsoft/Mastering-GitHub-Copilot-for-Paired-Programming

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选
Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment